ClinicalTrials.Veeva

Menu

Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan

K

Kaohsiung Medical University

Status

Completed

Conditions

HIV

Study type

Observational

Funder types

Other

Identifiers

NCT01697540
KMUHIRB-2012-05-05(I)

Details and patient eligibility

About

  1. Written informed consent must be obtained before any study specific procedures are undertaken.
  2. The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the new therapy. The investigators will follow the patients' lipid profile and any side effects and stop the observation till 36 months after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The patients' chart and all data will be delinked to protect the patients' right and privacy.

Enrollment

100 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HIV-infected patients who receive HAART therapy but have metabolic side effects.
  • Age over 20 years old

Exclusion criteria

  • Abnormal liver function: GOT or GPT 5 times over normal upper limit

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems